Barry, W., Chen, W., Sfakianos, G., Isner, P., Datto, M., Kuderer, N., … Berchuck, A. (2011). OP 54 A genomic-based signature of response to chemotherapy in ovarian cancer fails to predict clinical outcome in two independent cohorts. In European Journal of Cancer (Vol. 47, pp. S8–S8). Elsevier BV. https://doi.org/10.1016/s0959-8049(11)72620-x

Barry, W., W. Chen, G. Sfakianos, P. Isner, M. Datto, N. Kuderer, G. Lyman, A. Abernethy, G. Ginsburg, and A. Berchuck. “OP 54 A genomic-based signature of response to chemotherapy in ovarian cancer fails to predict clinical outcome in two independent cohorts.” In European Journal of Cancer, 47:S8–S8. Elsevier BV, 2011. https://doi.org/10.1016/s0959-8049(11)72620-x.

Barry W, Chen W, Sfakianos G, Isner P, Datto M, Kuderer N, et al. OP 54 A genomic-based signature of response to chemotherapy in ovarian cancer fails to predict clinical outcome in two independent cohorts. In: European Journal of Cancer. Elsevier BV; 2011. p. S8–S8.

Barry, W., et al. “OP 54 A genomic-based signature of response to chemotherapy in ovarian cancer fails to predict clinical outcome in two independent cohorts.” European Journal of Cancer, vol. 47, Elsevier BV, 2011, pp. S8–S8. Crossref, doi:10.1016/s0959-8049(11)72620-x.

Barry W, Chen W, Sfakianos G, Isner P, Datto M, Kuderer N, Lyman G, Abernethy A, Ginsburg G, Berchuck A. OP 54 A genomic-based signature of response to chemotherapy in ovarian cancer fails to predict clinical outcome in two independent cohorts. European Journal of Cancer. Elsevier BV; 2011. p. S8–S8.